HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.

Interview Questions:
1. Could you remind us of the importance of STEP-HFpEF
2. What was the study design and patient population?
3. What are the outcomes in terms of effect of semaglutide on exercise function?
4. What was the impact of a patient's frailty status?
4. What do these findings tell us about the future of obesity related heart failure treatment?
5. Are there any further knowledge gaps that need to be addressed?

Recorded remotely from Kansas City, US.

Editor: Jordan Rance
Video Specialist: David Ben-Harosh